Observational Registry Study of Quality of Life When Treating BTcP With Abstral
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This Observational Registry study is designed to collect self-reported Transmucosal Immediate
Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access
program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of
treatment with Abstral® through the use of Quality of Life and pain measurement tools
administered via questionnaire.